keyword
MENU ▼
Read by QxMD icon Read
search

Progressive multiple sclerosis treatment

keyword
https://www.readbyqxmd.com/read/29340646/visual-fixation-instability-in-multiple-sclerosis-measured-using-slo-oct
#1
Robert M Mallery, Pieter Poolman, Matthew J Thurtell, Jan M Full, Johannes Ledolter, Dorlan Kimbrough, Elliot M Frohman, Teresa C Frohman, Randy H Kardon
Purpose: Precise measurements of visual fixation and its instability were recorded during optical coherence tomography (OCT) as a marker of neural network dysfunction in multiple sclerosis (MS), which could be used to monitor disease progression or response to treatment. Methods: A total of 16 MS patients and 26 normal subjects underwent 30 seconds of scanning laser ophthalmoscope (SLO)-based eye tracking during OCT scanning of retinal layer thickness. Study groups consisted of normal eyes, MS eyes without prior optic neuritis (MS wo ON), and MS eyes with prior optic neuritis (MS + ON)...
January 1, 2018: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29332021/the-effects-of-reflexology-on-fatigue-and-anxiety-in-patients-with-multiple-sclerosis
#2
Afitap Ozdelikara, Seval Agcadiken Alkan
Context • Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system. In addition to the progressive nature of the disease, devastating symptoms adversely affect the patient's daily life and future expectations. This situation leads patients to seek complementary and alternative treatments. Objectives • This study was conducted to determine the effects of reflexology on fatigue severity and anxiety in patients with MS. Design • The research was a quasi-experimental, pretest-posttest design...
January 15, 2018: Alternative Therapies in Health and Medicine
https://www.readbyqxmd.com/read/29331092/deep-grey-matter-volume-loss-drives-disability-worsening-in-multiple-sclerosis
#3
Arman Eshaghi, Ferran Prados, Wallace Brownlee, Daniel R Altmann, Carmen Tur, M Jorge Cardoso, Floriana De Angelis, Steven H van de Pavert, Niamh Cawley, Nicola De Stefano, M Laura Stromillo, Marco Battaglini, Serena Ruggieri, Claudio Gasperini, Massimo Filippi, Maria A Rocca, Alex Rovira, Jaume Sastre-Garriga, Hugo Vrenken, Cyra E Leurs, Joep Killestein, Lukas Pirpamer, Christian Enzinger, Sebastien Ourselin, Claudia A M Gandini Wheeler-Kingshott, Declan Chard, Alan J Thompson, Daniel C Alexander, Frederik Barkhof, Olga Ciccarelli
OBJECTIVE: Grey matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS. METHODS: We analysed 3,604 brain high-resolution T1-weighted MRI scans from 1,417 participants: 1,214 MS patients (253 clinically-isolated syndrome[CIS], 708 relapsing-remitting[RRMS], 128 secondary-progressive[SPMS], 125 primary-progressive[PPMS]), over an average follow-up of 2...
January 13, 2018: Annals of Neurology
https://www.readbyqxmd.com/read/29331024/combination-therapy-of-lovastatin-and-ampk-activator-improves-mitochondrial-and-peroxisomal-functions-and-clinical-disease-in-eae-model
#4
Inderjit Singh, Devadoss J Samuvel, Seungho Choi, Nishant Saxena, Avtar K Singh, Jeseong Won
Recent studies report that loss and dysfunction of mitochondria and peroxisomes contribute to the myelin and axonal damage in multiple sclerosis (MS). In this study, we investigated the efficacy of lovastatin and AMPK activator (AICAR) combination on the loss and dysfunction of mitochondria and peroxisomes and myelin and axonal damage in the spinal cords, relative to the clinical disease symptoms, using a mouse model of experimental autoimmune encephalomyelitis (EAE, a model for MS). We observed that lovastatin and AICAR treatments individually provided partial protection of mitochondria/peroxisomes, myelin/axons, and thus partial attenuation of clinical disease in EAE mice...
January 13, 2018: Immunology
https://www.readbyqxmd.com/read/29330324/betaine-ameliorates-experimental-autoimmune-encephalomyelitis-by-inhibiting-dendritic-cell-derived-il-6-production-and-th17-differentiation
#5
Cuixia Yang, Weiming Lai, Jinfeng Zhou, Xinyuan Zheng, Yingying Cai, Wanjie Yang, Sirong Xie, Yuan Gao, Changsheng Du
IL-17-secreting T cells (Th17 cells) play a pathogenic role in multiple autoimmune diseases, including multiple sclerosis (MS), and dendritic cell (DC)-derived cytokines play pivotal roles in promoting the differentiation of naive CD4+ T cells into Th cell subsets (Th1 and Th17). Therefore, small molecules blocking the key cytokines produced by DCs will be beneficial in MS. In this article, we report that betaine treatment ameliorates MS pathogenesis by inhibiting DC-derived IL-6 production and Th17 differentiation...
January 12, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29324934/stem-cells-therapy-the-future-in-the-management-of-systemic-sclerosis-a-case-report
#6
Jung In Song, Silvanie Volz, Maria Eirini Liodaki, Peter Mailänder, Konstantinos Kalousis
OBJECTIVE: Systemic sclerosis (SSc) is a connective tissue disorder of unknown etiology, with heterogeneous clinical manifestations and chronic and often progressive course. The diffuse cutaneous form of SSc (dcSSc) is characterized by thickening of the skin (scleroderma) and distinctive involvement of multiple internal organs. Patients with limited cutaneous SSc (lcSSc) generally have long-standing Raynaud's phenomenon before other manifestations of SSc appear. Over the last decade the Interest of adipose-derived cell therapy in regenerative medicine has increased continuously...
September 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29321652/innate-ifn-%C3%AE-ameliorates-experimental-autoimmune-encephalomyelitis-and-promotes-myeloid-expansion-and-pdl-1-expression
#7
Madeleine P J White, Gill Webster, Faith Leonard, Anne Camille La Flamme
The innate immune system plays a central role in the immune-mediated pathology of multiple sclerosis, and is a therapeutic target for progressive disease. Recently, it has been demonstrated that MIS416, a novel immunomodulatory microparticle that activates NOD-2 and TLR-9-signaling, has disease-modifying activity in multiple sclerosis models. This activity is dependent on innate IFN-γ; however, the precise immune regulatory mechanisms amplified by MIS416 have not previously been determined. Using the experimental autoimmune encephalomyelitis model, MIS416 treatment was associated with IFN-γ-dependant expansion of Treg number and increased suppressive function; however, these cells did not account for disease reduction...
January 10, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29318902/interferon-%C3%AE-1a-and-%C3%AE-1b-for-patients-with-multiple-sclerosis-updates-to-current-knowledge
#8
Uwe Klaus Zettl, Michael Hecker, Orhan Aktas, Torsten Wagner, Paulus S Rommer
Although multiple sclerosis (MS) remains incurable, interferon beta (IFNβ) has been at the forefront of treatment for many years. Different formulations of IFNβ allow for different levels of exposure: low-dose/frequency with some agents, and high-dose/frequency with others. Areas covered: This review article discusses existing and emerging efficacy and safety data for IFNβ in MS. Clinical evidence of IFNβ efficacy has been generated and accumulated over many decades. During this time, key clinical trials have demonstrated the benefits of high-dose and/or high-frequency dosing of IFNβ-1a or β-1b, compared with lower levels of exposure, on outcome measures such as relapse rates, disability progression, disease progression and magnetic resonance imaging lesion outcomes...
January 10, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29318028/interferon-beta-1b-in-treatment-na%C3%A3-ve-paediatric-patients-with-relapsing-remitting-multiple-sclerosis-two-year-results-from-the-betapaedic-study
#9
Jutta Gärtner, Wolfgang Brück, Almuth Weddige, Hannah Hummel, Christiane Norenberg, Jörg-Peter Bugge
Background and objective: Study evaluating Betaferon(R)'s safety and tolerability in paediatric patients with multiple sclerosis (BETAPAEDIC) is a prospective, open-label observational multicentre study to assess the safety and effectiveness of interferon beta-1b in paediatric patients with relapsing-remitting multiple sclerosis. Methods: Treatment-naïve patients (12-16 years) scheduled to start interferon beta-1b were enrolled with follow-up visits every six months for two years...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29317954/a-multiple-treatment-comparison-of-eleven-disease-modifying-drugs-used-for-multiple-sclerosis
#10
Vida Hamidi, Elisabeth Couto, Tove Ringerike, Marianne Klemp
Background: Several disease-modifying drug therapies are available for the treatment of multiple sclerosis (MS). To ensure the most appropriate MS management, we assessed the effectiveness and cost-effectiveness of the disease-modifying medicines used for MS. Methods: We conducted a systematic review including 11 disease-modifying drugs used for treatment of adult patients diagnosed with relapsing-remitting MS. We performed a network meta-analysis using both direct and indirect evidence...
February 2018: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29314605/transcriptome-profiling-of-peripheral-blood-immune-cell-populations-in-multiple-sclerosis-patients-before-and-during-treatment-with-a-sphingosine-1-phosphate-receptor-modulator
#11
Ines C Angerer, Michael Hecker, Dirk Koczan, Luisa Roch, Jörg Friess, Annelen Rüge, Brit Fitzner, Nina Boxberger, Ina Schröder, Kristin Flechtner, Hans-Jürgen Thiesen, Alexander Winkelmann, Stefanie Meister, Uwe K Zettl
AIMS: Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator approved for the treatment of the relapsing form of multiple sclerosis (MS). It prevents the egress of lymphocyte subpopulations from lymphoid tissues into the circulation. Here, we explored the broad effects of fingolimod on gene expression in different immune cell subsets. METHODS: Utilizing 150 high-resolution microarrays from Affymetrix, we obtained the transcriptome profiles of 5 cell populations, which were separated from the peripheral blood of MS patients prior to and following oral administration of fingolimod...
January 3, 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29311122/experimental-autoimmune-encephalomyelitis-eae-as-animal-models-of-multiple-sclerosis-ms
#12
Simon Glatigny, Estelle Bettelli
Multiple sclerosis (MS) is a multifocal demyelinating disease of the central nervous system (CNS) leading to the progressive destruction of the myelin sheath surrounding axons. It can present with variable clinical and pathological manifestations, which might reflect the involvement of distinct pathogenic processes. Although the mechanisms leading to the development of the disease are not fully understood, numerous evidences indicate that MS is an autoimmune disease, the initiation and progression of which are dependent on an autoimmune response against myelin antigens...
January 8, 2018: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/29306740/efficacy-of-computer-based-cognitive-training-in-neuropsychological-performance-of-patients-with-multiple-sclerosis-a-systematic-review-and-meta-analysis
#13
REVIEW
Efthimios Dardiotis, Anastasia Nousia, Vasileios Siokas, Zisis Tsouris, Athina Andravizou, Alexios-Fotios A Mentis, Despoina Florou, Lambros Messinis, Grigorios Nasios
IMPORTANCE: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by relapses and a progressive course that may lead to accumulation of physical and cognitive disability. Cognitive training interventions seem to improve the cognitive performance of MS patients. The aim of the present meta-analysis is to quantitatively investigate the effect of computer-based cognitive rehabilitation on the neuropsychological performance of patients with MS...
December 24, 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29304807/laquinimod-ameliorates-excitotoxic-damage-by-regulating-glutamate-re-uptake
#14
Antonietta Gentile, Alessandra Musella, Francesca De Vito, Diego Fresegna, Silvia Bullitta, Francesca Romana Rizzo, Diego Centonze, Georgia Mandolesi
BACKGROUND: Laquinimod is an immunomodulatory drug under clinical investigation for the treatment of the progressive form of multiple sclerosis (MS) with both anti-inflammatory and neuroprotective effects. Excitotoxicity, a prominent pathophysiological feature of MS and of its animal model, experimental autoimmune encephalomyelitis (EAE), involves glutamate transporter (GluT) dysfunction in glial cells. The aim of this study was to assess whether laquinimod might exert direct neuroprotective effects by interfering with the mechanisms of excitotoxicity linked to GluT function impairments in EAE...
January 5, 2018: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29299124/fty-720-induces-apoptosis-in-neuroblastoma-via-multiple-signaling-pathways
#15
Ingo Lange, Italo Espinoza-Fuenzalida, Mourad Wagdy Ali, Laura Espana Serrano, Dana-Lynn T Koomoa
Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor. High-risk NB is difficult to treat due to the lack of response to current therapies and aggressive disease progression. Despite novel drugs, alternative treatments and multi-modal treatments, finding an effective treatment strategy for these patients continues to be a major challenge. The current study focuses on examining the effects of FTY-720 or fingolimod, a drug that is FDA-approved for refractory multiple sclerosis, in NB. The results showed that FTY-720 regulates multiple pathways that result in various effects on calcium signaling, ion channel activation and cell survival/death pathways...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29296926/evolution-trends-outcomes-and-economics-of-hematopoietic-stem-cell-transplantation-in-severe-autoimmune-diseases
#16
John A Snowden, Manuela Badoglio, Myriam Labopin, Sebastian Giebel, Eoin McGrath, Zora Marjanovic, Joachim Burman, John Moore, Montserrat Rovira, Nico M Wulffraat, Majid Kazmi, Raffaella Greco, Emilian Snarski, Tomas Kozak, Kirill Kirgizov, Tobias Alexander, Peter Bader, Riccardo Saccardi, Dominique Farge
Hematopoietic stem cell transplantation (HSCT) has evolved for >20 years as a specific treatment of patients with autoimmune disease (AD). Using European Society for Blood and Marrow Transplantation registry data, we summarized trends and identified factors influencing activity and outcomes in patients with AD undergoing first autologous HSCT (n = 1951; median age, 37 years [3-76]) and allogeneic HSCT (n = 105; median age, 12 years [<1-62]) in 247 centers in 40 countries from 1994 to 2015. Predominant countries of activity were Italy, Germany, Sweden, the United Kingdom, The Netherlands, Spain, France, and Australia...
December 26, 2017: Blood Advances
https://www.readbyqxmd.com/read/29277498/retinal-astrocytoma-regression-in-tuberous-sclerosis-patients-treated-with-everolimus
#17
Anat Bachar Zipori, Nasrin Tehrani, Asim Ali
Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) that has been approved by the US Food and Drug Administration for the treatment of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC). Retinal hamartomas, which are one of the major diagnostic features of TSC, tend to remain stable or gradually progress in the natural history of the disease. We report 2 patients with TSC treated with everolimus for SEGA in whom fundus photographs and spectral domain optical coherence tomography demonstrated regression of previously documented multiple retinal hamartomas in all 4 eyes...
December 19, 2017: Journal of AAPOS: the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
https://www.readbyqxmd.com/read/29276624/subcutaneous-interferon-%C3%AE-1a-three-times-weekly-and-the-natural-evolution-of-gadolinium-enhancing-lesions-into-chronic-black-holes-in-relapsing-and-progressive-multiple-sclerosis-analysis-of-prisms-and-spectrims-trials
#18
A Traboulsee, Dkb Li, R Tam, G Zhao, A Riddehough, J Fang, F Dangond, L Kappos
Background: Evolution of gadolinium-enhancing lesions into chronic black holes (CBH) may be reduced by interferon (IFN) therapy. Objective: The objective of this paper is to assess the effect of IFN β-1a and placebo on CBH evolution and disability in patients with relapsing-remitting multiple sclerosis (RRMS), as well as CBH evolution in patients with secondary progressive multiple sclerosis (SPMS). Methods: A post hoc, exploratory analysis of patients with RRMS and SPMS with monthly MRI scans (months -1 to 9) from two separate placebo-controlled clinical trials of IFN β-1a was conducted...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29274753/multiple-sclerosis-re-examined-essential-and-emerging-clinical-concepts
#19
REVIEW
Jonathan Zurawski, James Stankiewicz
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by exacerbations of neurological dysfunction due to inflammatory demyelination. Neurologic symptoms typically present in young adulthood and vary based on the site of inflammation, though weakness, sensory impairment, brainstem dysfunction and vision loss are common. MS occurs more frequently in women and its development is complex-genetics, hormones, geography, vitamin D, and viral exposure all play roles. Early MS is characterized by relapsing-remitting course and inflammation of the white matter though as patients age, the disease often transitions to a pathologically distinct secondary progressive phase with gradual disability accrual affecting gait, coordination and bladder function...
December 21, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/29273846/intrathecal-oligoclonal-bands-synthesis-in-multiple-sclerosis-is-it-always-a-prognostic-factor
#20
Jessica Frau, Luisa Maria Villar, Claudia Sardu, Maria Antonietta Secci, Lucia Schirru, Diana Ferraro, Giancarlo Coghe, Lorena Lorefice, Giuseppe Fenu, Roberta Bedin, Patrizia Sola, Maria Giovanna Marrosu, Eleonora Cocco
BACKGROUND: Oligoclonal IgM (OCMB) and IgG (OCGB) bands were found to be associated with poor multiple sclerosis (MS) prognosis. OBJECTIVE: We aimed to evaluate the prognostic value of OCMB/OCGB in a cohort of Sardinian MS patients. MATERIALS AND METHODS: We recruited patients from the University of Cagliari. They underwent lumbar puncture for diagnostic purposes. Demographic and the following clinical data were recorded: clinical course; time to reach EDSS 3 and 6; EDSS at last follow-up; and MS treatments...
December 22, 2017: Journal of Neurology
keyword
keyword
110166
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"